Abstract
TMPRSS11D (HAT) belongs to the large type II transmembrane serine protease (TTSP) family, participating in various biological and physiological processes. TMPRSS11D expression has been reported during squamous cell carcinogenesis, however, its expression during non-small cell lung cancer (NSCLC) development has not been studied. In this study, we determined the mRNA and protein expression of TMPRSS11D in NSCLC tumorous and matched adjacent normal tissues by quantitative reverse transcription PCR (qRT-PCR) and tissue microarray immunohistochemistry analysis (TMA-IHC) respectively. TMPRSS11D protein expression in tumorous tissues were correlated with NSCLC patients’ clinical characteristics and overall survival. Both TMPRSS11D mRNA and protein expression levels were significantly higher in NSCLC tumorous tissues than in adjacent normal tissues. High TMPRSS11D protein expression was associated with high TNM stages, and high TMPRSS11D protein expression is an independent prognostic marker in NSCLC. Based on our results, we conclude that TMPRSS11D could play a role in NSCLC development and progression. Because of its role in proteolysis of extracellular matrix, targeting TMPRSS11D may prevent the development of metastasis in NSCLC.
Highlights
Lung cancer is the leading cause of cancer death worldwide and in China [1,2,3,4]
TMPRSS11D mRNA level was significantly higher in non-small cell lung cancer (NSCLC) tumorous tissues than in adjacent normal tissues
TMPRSS11D mRNA expression level was significantly higher in NSCLC tumorous tissues (2.451 ± 0.2481) when compared to adjacent normal tissues (1.174 ± 0.1625) (P < 0.001) (Figure 1)
Summary
Lung cancer is the leading cause of cancer death worldwide and in China [1,2,3,4]. The estimated incidence and mortality of lung cancer in 2015 is 733.3 and 610.2 per 100,000 population respectively in China [5]. Lung cancer disproportionally affects men and urban populations than women and rural populations, and it is estimated that air pollution will be the primary cause of lung cancer in China by 2020 [6]. Less than 50% of NSCLC patients are diagnosed with stage I or II disease, which are amendable for surgical resection with curative intent [9]. Even among patients who undergo such complete and presumably curative surgical treatment, approximately 40–50% of patients will have and die from recurrent disease [10]. Novel prognostic markers and therapeutic targets are needed to improve the overall survival of NSCLC patients [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
